Stocktoria
OMNICELL, INC. OMCL
OMNICELL, INC. (OMCL) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $1.2B at a 0.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.85 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.103 |
| Retained earnings / assets | 0.195 |
| EBIT / assets | 0.003 |
| Equity / liabilities | 1.658 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| OMCL | OMNICELL, INC. | 7/9 | 3.07 | 889.4 | +6.5% |
| ZEPP | Zepp Health Corp | 5/9 | 0.31 | — | +41.8% |
| OSS | ONE STOP SYSTEMS, INC. | 4/9 | 11.23 | 79.1 | +31.2% |
| SCKT | SOCKET MOBILE, INC. | 2/9 | -15.54 | — | -19.6% |
| SMCI | Super Micro Computer, Inc. | 5/9 | 6.92 | 18.9 | +46.6% |
| AAPL | Apple Inc. | 8/9 | 2.31 | 37.2 | +6.4% |
| VFS | VinFast Auto Ltd. | 4/9 | -13.01 | — | +57.9% |
About OMNICELL, INC.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
FAQ
Is OMCL financially healthy?
OMNICELL, INC.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does OMCL pay a dividend?
No, OMNICELL, INC. does not currently pay a dividend.
How profitable is OMCL?
In FY2025, OMNICELL, INC. had a net margin of 0.2% and a return on equity of 0.2%.
Is OMCL overvalued or undervalued?
OMNICELL, INC. trades at about 928.3× trailing earnings — above its 10-year norm (10-year range 33.3×–1212.5×, median 138.1×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for OMCL?
The average Wall-Street price target for OMNICELL, INC. is $61.29, about 65.1% above the recent price, from 7 analysts (consensus: strong buy).
Is OMCL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on OMNICELL, INC.: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 889.4×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.